,
Hibar, D P
Westlye, L T
Doan, N T
Jahanshad, N
Cheung, J W
Ching, C R K
Versace, A
Bilderbeck, A C
Uhlmann, A
Mwangi, B
Krämer, B
Overs, B
Hartberg, C B
Abé, C
Dima, D
Grotegerd, D
Sprooten, E
Bøen, E
Jimenez, E
Howells, F M
Delvecchio, G
Temmingh, H
Starke, J
Almeida, J R C
Goikolea, J M
Houenou, J http://orcid.org/0000-0003-3166-5606
Beard, L M
Rauer, L
Abramovic, L
Bonnin, M
Ponteduro, M F
Keil, M
Rive, M M
Yao, N
Yalin, N
Najt, P
Rosa, P G
Redlich, R
Trost, S
Hagenaars, S http://orcid.org/0000-0001-9697-8596
Fears, S C
Alonso-Lana, S http://orcid.org/0000-0002-3063-6929
van Erp, T G M
Nickson, T
Chaim-Avancini, T M
Meier, T B
Elvsåshagen, T
Haukvik, U K
Lee, W H
Schene, A H
Lloyd, A J
Young, A H
Nugent, A
Dale, A M
Pfennig, A
McIntosh, A M
Lafer, B
Baune, B T
Ekman, C J
Zarate, C A
Bearden, C E
Henry, C
Simhandl, C
McDonald, C
Bourne, C
Stein, D J
Wolf, D H
Cannon, D M
Glahn, D C
Veltman, D J
Pomarol-Clotet, E
Vieta, E
Canales-Rodriguez, E J
Nery, F G
Duran, F L S
Busatto, G F
Roberts, G
Pearlson, G D
Goodwin, G M
Kugel, H http://orcid.org/0000-0002-4349-1984
Whalley, H C
Ruhe, H G
Soares, J C
Fullerton, J M
Rybakowski, J K
Savitz, J
Chaim, K T
Fatjó-Vilas, M
Soeiro-de-Souza, M G
Boks, M P
Zanetti, M V
Otaduy, M C G
Schaufelberger, M S
Alda, M
Ingvar, M
Phillips, M L
Kempton, M J
Bauer, M
Landén, M
Lawrence, N S
van Haren, N E M
Horn, N R
Freimer, N B
Gruber, O
Schofield, P R
Mitchell, P B
Kahn, R S
Lenroot, R
Machado-Vieira, R
Ophoff, R A
Sarró, S
Frangou, S
Satterthwaite, T D
Hajek, T
Dannlowski, U
Malt, U F
Arolt, V
Gattaz, W F
Drevets, W C
Caseras, X
Agartz, I
Thompson, P M
Andreassen, O A
Article History
Received: 3 August 2016
Revised: 4 February 2017
Accepted: 10 February 2017
First Online: 2 May 2017
Competing interests
: AMM has received funding from Lilly, Janssen and Pfizer. It is unconnected with the current work. TvE has a contract with Otsuka Pharmaceutical Inc. The contract is not related to this work. UFM participated in the speaker’s bureau for Lundbeck Norway and was a consultant for Takeda Pharmaceuticals. ACB has received salaries from P1vital Ltd, which is unrelated to this work. PGR trained personnel for Janssen Pharmaceuticals. It is unconnected with the current work. DPH and WCD are employed by Janssen Research and Development, LLC. MB has received grant/research support from Deutsche Forschungsgemeinschaft (DFG), Bundesministeriums für Bildung und Forschung (BMBF), American Foundation of Suicide Prevention. MB is/has been a consultant for AstraZeneca, Bristol Myers Squibb, Ferrer Internacional, Janssen, Lilly, Lundbeck, Merz, Neuraxpharm, Novartis, Otsuka, Servier, Takeda, and has received speaker honoraria from AstraZeneca, GlaxoSmithKline, Lilly, Lundbeck, Otsuka and Pfizer, which is all unrelated to this work. OAA has received speaker’s honorarium from Lundbeck, Otsuka and Lilly. The remaining authors declare no conflicts of interest. All authors have contributed to and approved the contents of this manuscript.